BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 15821586)

  • 1. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.
    Wu GJ; Peng Q; Fu P; Wang SW; Chiang CF; Dillehay DL; Wu MW
    Gene; 2004 Mar; 327(2):201-13. PubMed ID: 14980717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
    Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
    Chiang CF; Son EL; Wu GJ
    Prostate; 2005 Sep; 64(4):408-18. PubMed ID: 15789364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
    Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
    Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Yeh IT; Reddick RL; Kumar AP
    Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
    Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
    Tepaamorndech S; Huang L; Kirschke CP
    Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
    Bethel CR; Bieberich CJ
    Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic prostate cancer in a transgenic mouse.
    Gingrich JR; Barrios RJ; Morton RA; Boyce BF; DeMayo FJ; Finegold MJ; Angelopoulou R; Rosen JM; Greenberg NM
    Cancer Res; 1996 Sep; 56(18):4096-102. PubMed ID: 8797572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.